Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

BACKGROUND Recent reports suggest a possibly protective effect for statins in patients with Alzheimer disease. This association could be due to indication bias, i.e., people who elect to take lipid-lowering agents (LLAs) may be healthier than those who do not, so that it may be these other health factors that explain their lower risk of dementia. OBJECTIVES To examine the association between the use of LLAs and dementia, adjusting for other markers of health, and to investigate factors associated with LLA use. DESIGN A cohort study of LLA use and a case-control study of dementia in relation to LLA use, in a secondary analysis of the Canadian Study of Health and Aging. SETTING A nationally representative population-based survey of Canadians 65 years and older. PARTICIPANTS To examine features associated with statin use, we evaluated data on 2305 people for whom health information, drug use, and cognitive status were known. To examine the relationship between LLA use and dementia, we selected incident cases of dementia (n = 492, of whom 326 had Alzheimer disease) that occurred between the first and second waves of the study. Control subjects were 823 persons examined during the first and second phases of the Canadian Study of Health and Aging who had no cognitive impairment. RESULTS Use of LLAs was significantly (P<.001) more common in younger (65-79 years) than in older (> or = 80 years) people. It was not associated with other factors indicating a healthy lifestyle, but was associated with a history of smoking and hypertension. Use of statins and other LLAs reduced the risk of Alzheimer disease in subjects younger than 80 years, an effect that persisted after adjustment for sex, educational level, and self-rated health (odds ratio, 0.26; 95% confidence interval, 0.08-0.88). There was no significant effect in subjects 80 years and older. CONCLUSIONS While the possibility of indication bias in the original observations cannot be excluded, it was not demonstrated in LLA use in this study. Lipid-lowering agent use was associated with a lower risk of dementia, and specifically of Alzheimer disease, in those younger than 80 years. Further research is warranted.

[1]  Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis , 2001 .

[2]  Gustavo Roman,et al.  Vascular cognitive impairment , 2003, The Lancet Neurology.

[3]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[4]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[5]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[6]  R. Haley,et al.  Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? , 2000, Archives of neurology.

[7]  M. Bell,et al.  The Women's Health Initiative: a heart-to-HRT conversation. , 2000, Mayo Clinic proceedings.

[8]  B. L. Beattie,et al.  Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. , 1996, Neuroepidemiology.

[9]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[10]  A. Nissinen,et al.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. , 1998, Neuroepidemiology.

[11]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[12]  B. Reisberg,et al.  Vascular cognitive impairment , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[14]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[15]  B L Miller,et al.  Estrogen for Alzheimer’s disease in women , 2000, Neurology.

[16]  S. Cummings,et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.

[17]  D. Hogan,et al.  Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. , 1995, Archives of neurology.

[18]  The incidence of dementia in Canada , 2000, Neurology.

[19]  M. Breteler,et al.  Vascular risk factors for Alzheimer’s disease: An epidemiologic perspective , 2000, Neurobiology of Aging.

[20]  V. Hachinski,et al.  Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. , 1997, Archives of neurology.

[21]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[22]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[23]  R. Mayeux,et al.  APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.

[24]  Vascular factors and Alzheimer disease. , 1999, Alzheimer disease and associated disorders.

[25]  J. Lindsay,et al.  Physical activity and risk of cognitive impairment and dementia in elderly persons. , 2001, Archives of neurology.

[26]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.